Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Patients with chronic kidney disease (CKD) have been found to show markedly increased rates of end-stage renal disease, major adverse cardiovascular and cerebrovascular events (MACCEs), and mortality. Therefore, new biomarkers are required for the early detection of such clinical outcomes in patients with CKD. We aimed to determine whether the level of circulating renalase was associated with CKD progression, MACCEs, and all-cause mortality, using data from a prospective randomized controlled study, Kremezin STudy Against Renal disease progression in Korea (K-STAR; NCT 00860431). Methods: A retrospective analysis of the K-STAR data was performed including 383 patients with CKD (mean age, 56.4 years; male/female, 252/131). We measured circulating renalase levels and examined the effects of these levels on clinical outcomes. Results: The mean level of serum renalase was 75.8 ± 34.8 μg/mL. In the multivariable analysis, lower hemoglobin levels, higher serum creatinine levels, and diabetes mellitus were significantly associated with a higher renalase levels. Over the course of a mean follow-up period of 56 months, 25 deaths and 61 MACCEs occurred. Among 322 patients in whom these outcomes were assessed, 137 adverse renal outcomes occurred after a mean follow-up period of 27.8 months. Each 10- μg/mL increase in serum renalase was associated with significantly greater hazards of all-cause mortality and adverse renal outcomes (hazard ratio [HR] = 1.112, p = 0.049; HR = 1.052, p = 0.045). However, serum renalase level was not associated with the rate of MACCEs in patients with CKD. Conclusions: Our results indicated that circulating renalase might be a predictor of mortality and adverse renal outcomes in patients with CKD.
Abstract
Background/Aims: Patients with chronic kidney disease (CKD) have been found to show markedly increased rates of end-stage renal disease, major adverse cardiovascular and cerebrovascular events (MACCEs), and mortality. Therefore, new biomarkers are required for the early detection of such clinical outcomes in patients with CKD. We aimed to determine whether the level of circulating renalase was associated with CKD progression, MACCEs, and all-cause mortality, using data from a prospective randomized controlled study, Kremezin STudy Against Renal disease progression in Korea (K-STAR; NCT 00860431). Methods: A retrospective analysis of the K-STAR data was performed including 383 patients with CKD (mean age, 56.4 years; male/female, 252/131). We measured circulating renalase levels and examined the effects of these levels on clinical outcomes. Results: The mean level of serum renalase was 75.8 ± 34.8 μg/mL. In the multivariable analysis, lower hemoglobin levels, higher serum creatinine levels, and diabetes mellitus were significantly associated with a higher renalase levels. Over the course of a mean follow-up period of 56 months, 25 deaths and 61 MACCEs occurred. Among 322 patients in whom these outcomes were assessed, 137 adverse renal outcomes occurred after a mean follow-up period of 27.8 months. Each 10- μg/mL increase in serum renalase was associated with significantly greater hazards of all-cause mortality and adverse renal outcomes (hazard ratio [HR] = 1.112, p = 0.049; HR = 1.052, p = 0.045). However, serum renalase level was not associated with the rate of MACCEs in patients with CKD. Conclusions: Our results indicated that circulating renalase might be a predictor of mortality and adverse renal outcomes in patients with CKD.
참고문헌 (34)
- Spasovski G, "Proteomics in chronic kidney disease : the issues clinical nephrologists need an answer for", Proteomics Clin Appl, 5, pp.233~240 (2011)
- Barsoum RS, "Chronic kidney disease in the developing world", N Engl J Med, 354, pp.997~999 (2006)
- Maciorkowska D, "Circulating renalase, catecholamines, and vascular adhesion protein 1in hypertensive patients", J Am Soc Hypertens, 9, pp.855~864 (2015)
- Desir GV, "Human renalase : a review of its biology, function, and implications for hypertension", J Am Soc Hypertens, 6, pp.417~426 (2012)
- Xu J, "Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure", J Clin Invest, 115, pp.1275~1280 (2005)
- Li G, "Catecholamines regulate the activity, secretion, and synthesis of renalase", Circulation, 117, pp.1277~1282 (2008)
- Guo X, "Renalase : its role as a cytokine, and an update on its association with type 1 diabetes and ischemic stroke", Curr Opin Nephrol Hypertens, 23, pp.513~518 (2014)
- Zbroch E, "Circulating levels of renalase, norepinephrine, and dopamine in dialysis patients", Ren Fail, 35, pp.673~679 (2013)
- Wang F, "Serum renalase is related to catecholamine levels and renal function", Clin Exp Nephrol, 19, pp.92~98 (2015)
- Przybylowski P, "Serum renalase depends on kidney function but not on blood pressure in heart transplant recipients", Transplant Proc, 43, pp.3888~3891 (2011)
- Malyszko J, "Renalase, a novel regulator of blood pressure, is predicted by kidney function in renal transplant recipients", Transplant Proc, 43, pp.3004~3007 (2011)
- Gluba-Brzozka A, "Markers of increased cardiovascular risk in patients with chronic kidney disease", Lipids Health Dis, 13, pp.135~ (2014)
- Desir GV, "Renalase lowers ambulatory blood pressure by metabolizing circulating adrenaline", J Am Heart Assoc, 1, pp.e002634~ (2012)
- Desir GV, "Role of renalase in the regulation of blood pressure and the renal dopamine system", Curr Opin Nephrol Hypertens, 20, pp.31~36 (2011)
- Wang F, "Renalase might be associated with hypertension and insulin resistance in type 2 diabetes", Ren Fail, 36, pp.552~556 (2014)
- Ghosh SS, "Cardiac hypertrophy in neonatal nephrectomized rats : the role of the sympathetic nervous system", Pediatr Nephrol, 24, pp.367~377 (2009)
- Baraka A, "Cardioprotective effect of renalase in 5", 6 nephrectomized rats, 2012, pp.17, 412~416
- Cha RH, "A randomized, controlled trial of oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction", Clin J Am Soc Nephrol, 11, pp.559~567 (2016)
- Cheng JM, "Circulating osteoglycin and NGAL", MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography, 2014, pp.34, 1078~1084
- Muhlestein JB, "Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes : the FACTOR-64 randomized clinical trial", JAMA, 312, pp.2234~2243 (2014)
- Ho KK, "The epidemiology of heart failure: the Framingham Study", J Am Coll Cardiol, 22(4 Suppl A), pp.6A~13A (1993)
- Westin GG, "Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia", J Am Coll Cardiol, 63, pp.682~690 (2014)
- Wang L, "Renalase prevents AKI independent of amine oxidase activity", J Am Soc Nephrol, 25, pp.1226~1235 (2014)
- Milani M, "FAD-binding site and NADP reactivity in human renalase : a new enzyme involved in blood pressure regulation", J Mol Biol, 411, pp.463~473 (2011)
- Boomsma F, "Renalase, a catecholamine-metabolising enzyme?", J Neural Transm (Vienna), 114, pp.775~776 (2007)
- Malyszko J, "Renalase is removed by kidneys and during dialysis: excess related to CKD complications?", Curr Vasc Pharmacol, 13, pp.134~140 (2015)
- Koc-Zorawska E, "VAP-1, a novel molecule linked to endothelial damage and kidney function in kidney allograft recipients", Kidney Blood Press Res, 36, pp.242~247 (2012)
- Wybraniec MT, "Low plasma renalase concentration in hypertensive patients after surgical repair of coarctation of aorta", J Am Soc Hypertens, 8, pp.464~474 (2014)
- Zbroch E, "Renalase, a novel enzyme involved in blood pressure regulation, is related to kidney function but not to blood pressure in hemodialysis patients", Kidney Blood Press Res, 35, pp.395~399 (2012)
- Gu R, "Renalase deficiency in heart failure model of rats : a potential mechanism underlying circulating norepinephrine accumulation", PLoS One, 6, pp.e14633~ (2011)
- Dziedzic M, "Relationship between renalase and N-terminal pro-B-type natriuretic peptide(NT pro-BNP)in haemodialysis patients", Ann Agric Environ Med, 21, pp.132~135 (2014)
- Malyszko J, "Hypertension and kidney disease: is renalase a new player or an innocent bystander?", J Hypertens, 30, pp.457~462 (2012)
- Eisenhofer G, "Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines", J Clin Endocrinol Metab, 80, pp.3009~3017 (1995)
- Schlaich MP, "Sympathetic activation in chronic renal failure", J Am Soc Nephrol, 20, pp.933~939 (2009)